Page last updated: 2024-10-29

isradipine and Obesity

isradipine has been researched along with Obesity in 1 studies

Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Obesity affects the efficacy of metoprolol and isradipine in reducing blood pressure."5.07Obesity as a determinant for response to antihypertensive treatment. ( Gatzka, C; Rüddel, H; Schächinger, H; Schmieder, RE; Schobel, H, 1993)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schmieder, RE1
Gatzka, C1
Schächinger, H1
Schobel, H1
Rüddel, H1

Trials

1 trial available for isradipine and Obesity

ArticleYear
Obesity as a determinant for response to antihypertensive treatment.
    BMJ (Clinical research ed.), 1993, Aug-28, Volume: 307, Issue:6903

    Topics: Blood Pressure; Body Mass Index; Double-Blind Method; Humans; Hypertension; Isradipine; Male; Metopr

1993